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Medicare-paid Naloxone: Trends in Non-metropolitan and Metropolitan Areas 
Chris Delcher, PhD; Yue Cheng, MS; Minji Sohn, PhD; Jeffery Talbert, PhD; Patricia R. Freeman, PhD 
Overview of Key Findings 
▪ Medicare pays for the largest share (>30%) of naloxone dispensed from retail pharmacies in non-
metropolitan areas. 
▪ Medicare-paid dispensing has grown since 2013, but from 2017-2018 dispensing growth in non-
metropolitan areas slowed considerably compared to metropolitan areas (42% v 121%, 
respectively). 
▪ As of 2018, the rate of naloxone dispensing to Medicare enrollees in metropolitan areas was 
approximately double that in non-metropolitan areas (4.9 v 2.9 per 1,000 enrollees, respectively).  
 
Introduction  
The U.S. Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration, and 
other state and federal public health agencies have made increasing access to naloxone, the life-saving 
opioid overdose reversal medication, a national priority.1-3 For example, in April 2018, the U.S. Surgeon 
General specifically encouraged the use of naloxone with an emphasis on groups at higher risk for overdose 
such as those receiving high-dose prescription opioids.4 A sizable segment of Medicare enrollees would 
likely benefit from access to naloxone given that approximately 28% of Medicare Part D beneficiaries with 
new opioid use were prescribed high doses.5   
According to the U.S. Centers for Medicare & Medicaid Services (CMS), naloxone dispensing in Medicare 
has increased markedly in recent years. CMS reported that naloxone prescriptions in Medicare Part D 
increased 141% from 2016 to 2017 and 148% from 2017 to 2018.1 Sohn et al. found that Medicare’s share 
of the payer volume of naloxone had also increased from 11% to 29% from 2011 to 2017.6 The most recent 
national data available (2018) indicate that Medicare Part D is the payer for more than one-third of all 
naloxone dispensed from retail pharmacies.7 This is not surprising given that the prevalence of both chronic 
pain and high impact chronic pain is higher in persons over age 65.8 Interestingly, these data also show that 
prevalence of chronic and high impact chronic pain increases with rurality. However, existing national and 
state analyses do not provide any insight into naloxone access differences by metropolitan and non-
metropolitan areas. Ensuring naloxone access in non-metropolitan areas is an important goal given that 
these areas have rates of drug overdose deaths on par with those in metropolitan areas and opioid-related 
mortality grew by 721% in non-metropolitan areas from 1999-2016.9 Furthermore, 72% of rural counties 
lack an opioid treatment program (OTP), nearly 65% and 81% of non-metropolitan counties lack a 
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psychiatrist or psychiatric nurse practitioner, respectively, and providers in rural areas are less likely to 
receive promotional material for opioid use disorder medications. In addition, a larger proportion of the 
rural population is 65 and older.10–14 We are aware of only one study (2019) showing that non-metropolitan 
counties were less likely to be high-naloxone dispensing areas compared to metropolitan counties.7  
Given these gaps, the purpose of this policy brief is to examine trends in Medicare-paid naloxone 
dispensing rates in non-metropolitan versus metropolitan areas from 2014 to 2018. 
Methods 
The IQVIA National Prescription Audit (NPA) provided national estimated counts of naloxone dispensed. 
The NPA covers nearly 90% of all-payer, naloxone-dispensed transactions and is weighted to represent 
100% of naloxone prescriptions from retail pharmacies in the U.S. The NPA provided information on 
product, month, payer type, state, 3-digit ZIP Code of the pharmacy, and dispensing count for all 50 states 
and the District of Columbia. Payer types included cash, commercial insurance, Medicare Part D, Medicaid 
Fee for Service (FFS), and Medicaid managed care.  
The data were aggregated to the 3-digit ZIP Code (929 areas comprising approximately 42,000 5-digit ZIP 
Codes), a geographic unit used by data providers to avoid the risk of inadvertent statistical disclosure.15 
Therefore, to examine dispensing by metropolitan and non-metropolitan areas, we estimated county-level 
naloxone dispensing by 1) acquiring the population in ZIP Code tabulation areas (ZCTA),16 which 
approximate 5-digit ZIP Codes located in 3-digit ZIP Codes; 2) linked ZCTAs to counties; and 3) weighted 
3-digit counts based on county populations. ZCTAs and the crosswalk file are both available from the U.S. 
Census Bureau.17 The method and analytic code was provided by Sullivan et al (2020).16 Metropolitan and 
non-metropolitan areas were defined using the Rural-Urban Continuum Codes (2013) where county 
designations 1-3 were metropolitan and 4-9 were non-metropolitan.18 
To calculate calendar year annual dispensing rates per Medicare enrollees in Part D prescription plans, we 
divided the annual count of naloxone paid for by Medicare by the annual number of enrollees in Medicare 
Part D stratified by metropolitan and non-metropolitan areas. Medicare enrollment data were available 
from 2015 to 2018.19   
Because implementation of state laws mandating the co-prescribing of naloxone to persons at risk for 
opioid overdose can abruptly and significantly increase the rate of naloxone dispensed in states passing 
them,20 we performed a sensitivity analysis to see if the 2018 rate difference could be attributable to the 
inclusion of states with mandatory versions of these laws in either 2017 (delayed effects) or 2018. These 
states were Arizona, Florida, New Mexico, Rhode Island, Virginia, Vermont, and Washington.21   
Findings 
Nationally, naloxone prescriptions paid for by Medicare increased by 216% between 2016 and 2017 and 
120% between 2017 and 2018 (Table 1). The growth rate in the most recent period (120%) was 
considerably higher than for the other payer types (Medicaid FFS: 54%, Medicaid MCO: 82%, 
Commercial: 42%). Cash payments declined by 43%.  
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Table 1. Percentage change in volume of Medicare-paid naloxone prescriptions dispensed by retail 









*Although consistent, the percentage change in this study is different from 
 that reported by CMS and may be due to methodological differences.   
 
Since 2014, Medicare-paid naloxone dispensing has been higher in non-metropolitan areas (~19% in 2014, 
~38% in 2018) compared to metropolitan areas (~16% in 2014, ~36% in 2018). As of 2018, Medicare 
surpassed commercial payers as the largest payer of naloxone in both non-metropolitan and metropolitan 
areas of the United States (see Table 2).  
 
Table 2. The percentages of naloxone prescriptions dispensed from retail pharmacies by payer types in 
metropolitan and non-metropolitan areas by year.  














Cash 73.6% 51.4% 43.8% 31.5% 24.4% 19.8% 12.6% 9.4% 6.5% 6.7% 3.4% 2.2% 
Commercial 
Insurance 17.7% 23.8% 27.6% 33.6% 30.2% 36.6% 34.4% 44.9% 34.0% 39.2% 30.2% 33.2% 
Fee-for-
service 
Medicaid 2.8% 8.3% 7.8% 12.0% 15.5% 14.6% 13.2% 13.1% 12.7% 11.7% 12.9% 10.8% 
Managed 
Care 
Medicaid 0.2% 4.8% 2.2% 7.4% 7.8% 11.6% 10.5% 11.9% 14.2% 15.9% 15.2% 17.9% 
Medicare 
Part D 5.7% 11.8% 18.6% 15.6% 22.2% 17.5 % 29.3% 20.6% 32.6% 26.4% 38.3% 36.0% 
 
Also, since 2013, Medicare-paid naloxone dispensing has essentially increased by triple-digit percentages 
in both metropolitan and non-metropolitan areas (Table 3). In 2018, Medicare-paid naloxone dispensing 
showed positive growth rates of 42% and 137% in non-metropolitan and metropolitan areas, respectively, 
but this was substantially slower growth than in all prior years. Examining these rates as year-over-year 
ratios in metropolitan/non-metropolitan areas, ratios remained consistently on par from 2014 to 2017 (i.e., 
close to 1.0). However, in 2018, Medicare-paid naloxone dispensing growth in metropolitan areas outpaced 
that in non-metropolitan areas by more than 3 times (3.26).   
 
% Change 
Payer type 2016 to 2017  2017 to 2018 
Medicare* 216% 120% 
Medicaid fee-for-service 125% 54% 
Medicaid managed care organization 231% 82% 
Commercial 121% 42% 
Cash 72% -43% 
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Table 3. Number of Medicare-paid naloxone prescriptions from retail pharmacies, percentage change 
and change ratio in non-metropolitan and metropolitan areas in the U.S., 2013 to 2018. 
 
The Medicare-paid naloxone dispensing rate (Table 4) increased nationally from 0.12 per 1,000 
beneficiaries in 2015 to 4.56 per 1,000 in 2018. Dispensing rates in metropolitan and non-metropolitan 
areas (Figure 1, Table 5) were largely on par until 2018 when rates in metropolitan areas approximately 
doubled (1.72) those in non-metropolitan areas (4.92 compared to 2.85 per 1,000 Medicare enrollees, 
respectively). This result is consistent when examining the rate per 1,000 using the number of county 
residents older than 65 as the denominator.  
 
Table 4. Naloxone dispensing from retail pharmacies to Medicare Part D enrollees in the U.S., 2015 to 
2018. 
Year Naloxone dispensed (No.) Medicare enrollees (No.) Rate (per 1000) 
2015 4,654 38,019,814 0.12 
2016 28,534 40,597,528 0.70 
2017 89,981 42,125,229 2.14 
2018 198,783 43,634,677 4.56 
 
Table 5. Naloxone dispensing from retail pharmacies to Medicare Part D enrollees in non-metropolitan 
and metropolitan areas in the U.S., 2015 to 2018. 
 Non-metropolitan Metropolitan 








2015 672 6,448,389 0.10 3,982 31,571,425 0.13 
2016 4,558 7,229,972 0.63   23,976 33,367,556 0.72 
2017 15,337 7,431,717 2.06 74,643 34,693,512 2.15 
2018 21,793 7,645,066 2.85 176,989 35,989,611 4.92 
Note: The rate per 1,000 using number of residents > 65 years old in non-metropolitan areas was 0.12, 0.55, 1.86, and 2.48; 




 Non-metropolitan Metropolitan Total Change Ratio 
Year  No. 
 % Change  
from prior 
year No. 
 % Change  
from prior 
year No. 





2014 119 573% 911 519% 1031 525% 0.91 
2015 672 460% 3,982 337% 4,654 351% 0.73 
2016 4,558 578% 23,976 502% 28,534 513% 0.87 
2017 15,337 236% 74,643 211% 89,981 215% 0.89 
2018 21,793 42% 176,989 137% 198,783 121% 3.26 
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Figure 1. Medicare-paid naloxone dispensing rate per 1,000 enrollees in Medicare Part D in non-




In the sensitivity analysis, after excluding states with co-prescribing laws, the rate ratio was somewhat 
attenuated (1.63) but could not completely account for the difference between non-metropolitan and 
metropolitan areas. 
Discussion 
As of 2018, Medicare Part D was the largest single payer (by volume percentage) of naloxone prescriptions 
in both non-metropolitan and metropolitan areas of the United States. Our findings suggest that Medicare-
paid dispensing rates in metropolitan areas have begun to outpace those in non-metropolitan areas. To a 
certain degree, this trend may appropriately reflect the recognition that urban areas of the United States 
have experienced higher overdose death rates involving synthetic opioids other than methadone compared 
to rural areas since 2015.22 Even so, as naloxone prescriptions are dispensed to patients from community 
pharmacies, changes in the number of pharmacies in non-metropolitan areas could lead to disparities in 
dispensing. Previous research has shown that the number of independently owned rural pharmacies 
declined by 16.1% from 2003-2018, raising concerns that areas dependent on a sole pharmacy are at risk of 
losing access to many essential clinical services should that pharmacy close.23 Further research is needed to 
understand the relationship between dispensing disparities and pharmacy closures.  
Our findings are largely consistent with the CDC’s analysis of all-payer naloxone, but their analysis 
suggests that the disparity is driven by increasing rates in micropolitan areas versus rural areas (1.4 times 
higher) in 2018.7 Ongoing efforts are needed to monitor these dispensing trends with improved urban/rural 
specification to avoid preventable health care access barriers.  
CMS initiatives implemented during and after our study period will warrant future examination. Three 
policy changes may provide insight for future research. First, more recent data may allow us to examine 
whether the U.S. Surgeon General’s effort to increase naloxone use in 2018 may have contributed to uptake 
differences in metropolitan versus non-metropolitan areas.24 Second, in 2019, CMS launched a series of 
initiatives to address opioid misuse, including encouraging Medicare Part D plan sponsors to lower cost-
sharing for naloxone as out-of-pocket costs for naloxone were still relatively high for this period.25,26 Third, 
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research is needed into whether the dispensing disparities that we found are driven by differences in the risk 
profile of Medicare populations living in these areas. The CDC found that naloxone prescriptions among 
Medicare Part D patients had increased for some high-risk enrollees as recommended. However, only a 
small proportion of Medicare enrollees at the highest risk of overdose were being co-prescribed 
naloxone.7,27 Further, the CDC found that as the percentage of the population with Medicare increased, so 
too did the likelihood of a county being a low naloxone dispensing area after controlling for rural status.7 
Focusing on Medicare-paid naloxone is important partly because a recent report indicated that opioid 
prescriptions in Medicare increased by 2% from 2011 to 2019, whereas other payers saw double-digit 
decreases.28  
Limitations. Medicare Part D is only a subset of Medicare patients and does not include all patients in fee-
for-service or Medicare Advantage plans. Naloxone prescription counts in metropolitan and non-
metropolitan areas are based on estimates derived from statistical methods that extrapolate the volume of 
naloxone dispensed in pharmacies to the county level. Although patients are expected to live relatively 
close to their pharmacy, pharmacy availability in non-metropolitan areas is dynamic and our findings may 
not reflect residential context.29 Furthermore, the county population data available cover only 2010, and 
metropolitan/non-metropolitan designations are from 2013. More research is planned to understand the 
variability in naloxone dispensing introduced by this method. Even so, metropolitan and non-metropolitan 
areas are still relatively large aggregations of counties that may mitigate some of this error, and our results 
are comparable to the CDC’s in 2018 which had access to county-level data. Race/ethnicity data are not 
available for our naloxone dispensing data. Our data may not be comparable to more recent analyses due to 
a methodology change from IQVIA.30 
Conclusion 
We expect Medicare to remain a critical payer for naloxone in the United States. Medicare beneficiaries 
visit retail pharmacies more frequently than their primary care physicians,31 especially in non-metropolitan 
areas. Continued emphasis on retail pharmacy distribution of naloxone in these areas is warranted, 
especially as opioid prescriptions continue to increase for the Medicare population in parallel to concerning 
increases in opioid use disorder prevalence in this population.32  
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